|
NF Preclinical Consortium – RFA Open for $3.5M Expansion Funding
In 2007, the Children’s Tumor Foundation invested $4M to launch the Neurofibromatosis Preclinical Consortium (NFPC) to test
candidate drug therapies for neurofibromatosis in NF1 and NF2 models; compare the responses of different NF tumors to the
same drug; and identify candidate clinical therapies. Though a competitive process, six Centers were selected – four NF1 and
two NF2. NFPC has successfully established a preclinical drug testing pipeline and formed productive collaborations with
industrial partners such as Novartis and Genentech. NFPC has been CTF’s most significant research investment to date.
The current cycle of NFPC funding concludes June 30, 2011.
CTF is currently seeking applications from NF2 Centers to join this initiative. AT THIS TIME WE ARE NOT SOLICITING APPLICATIONS FROM NF1 CENTERS.
Funding is available for UP TO THREE NF2-focused NFPC Centers.
Download the NFPC RFA 2011 here.
Applications must be received by 5:00PM EST Friday June 24, 2011.
It is anticipated that successful applicants will be notified early August, 2011.
Click HERE to view the NFPC Brochure.
NF Preclinical Consortium Centers
-
University of California, San Francisco
Director: Kevin Shannon, MD
Tumor Focus: NF1 myeloid leukemia
-
Washington University School of Medicine
Director: David Gutmann, MD, Ph.D.
Tumor Focus: NF1 optic pathway glioma
-
Cincinnati Children’s Hospital Medical Center
Director: Timothy Cripe, MD, Ph.D.
Deputy Director: Nancy Ratner, Ph.D.
Tumor Focus: NF1 plexiform tumors & dermal neurofibromas
-
House Ear Institute
Director: Marco Giovannini, MD, Ph.D.
Tumor Focus: NF2 schwannoma, meningioma
-
Harvard Med School/Mass General Hospital
Director: Andrea McClatchey, Ph.D.
Tumor Focus: NF2 schwannoma, meningioma
-
Harvard Medical School/Brigham & Women’s Hospital
Director: Karen Cichowski, Ph.D.
Deputy Directors: Thomas De Raedt, Ph.D. & Ophelia Maertens, Ph.D.
Tumor Focus: NF1 malignant peripheral nerve sheath tumors.
NF Preclinical Consortium External Advisory Board (EAB)
-
Jay Gibbs, Ph.D. (Chair), AstraZeneca Pharmaceuticals
-
Gideon E. Bollag, Ph.D., Plexxikon Inc.
-
Sara A. Courtneidge, Ph.D. , The Burnham Inst. for Medical Research
-
Michael J. Morin, Ph.D., Oncovia, Inc.
-
Frank McCormick, Ph.D., University of California, San Francisco
-
Edward Stern, Esq., Legal Counsel to the CTF Medical Advisory Committee
EAB Emeritus Members
-
Larry Gelbert, Ph.D., Eli Lilly and Company
-
Filippo G. Giancotti, M.D., Ph.D. Memorial Sloan-Kettering Cancer Center
-
Janet M Hock, BDS, Ph.D., Maine Institute for Human Genetics and Health
-
Christopher L. Moertel, MD, Children's Hospitals and Clinics of Minnesota
-
Roger J. Packer, MD, Children’s National Medical Center
Questions? Contact:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
This e-mail address is being protected from spambots. You need JavaScript enabled to view it , Chief Scientific Officer
|
